FRESENIUS MEDICAL - DE0005785802 (Stock)
Stuttgart
| Price | Diff.% | Date & Time | Bid volume | Bid | Ask | Ask volume |
|---|---|---|---|---|---|---|
46,51 EUR
|
0,8894% | 14.07.2025 09:50 | 861,00 | 46,50 | 46,50 | 861,00 |
| Contact | |
|---|---|
|
|
Fresenius Medical Care AG Else-Kröner-Strasse 1 61352, Bad Homburg, DE |
| Phone | +49-6172-609-0 |
| Fax | + |
| marketing.international@... | |
| Internet | http://www.freseniusmedicalcare.com/de |
| IR Contact/PR Contact | -/- |
| Symbol | FME |
| End of financial year | 31.12.2025 |
| Issued capital | 13.573.285.380,00 EUR |
| Shareholders | |
|---|---|
| Freefloat | 50,72% |
| Fresenius SE & Co. KGaA | 28,55% |
| Dodge & Cox | 4,98% |
| Artisan Partners LP | 3,01% |
| Harris Associates LP | 2,98% |
| The Vanguard Group, Inc. | 2,69% |
| Pzena Investment Management LLC | 1,99% |
| DWS Investment GmbH | 1,80% |
| BlackRock Fund Advisors | 1,55% |
| Geode Capital Management LLC | 0,90% |
| BlackRock Advisors (UK) Ltd. | 0,83% |
| Board | |
|---|---|
| Helen Ping Giza | Chairman of Managing Board |
| Martin Fischer | Member of Executive Committee |
| M.D.,Ph.D. Katarzyna Mazur-Hofsaess | Member of Executive Committee |
| Jörg Häring | Member of Executive Committee |
| Craig Cordola | Member of Executive Committee |
| Dr. Frank Maddux | Member of Executive Committee |
| Michael Sen | Chairman of Supervisory Board |
| Sara Hennicken | Member of Supervisory Board |
| Shervin Korangy | Member of Supervisory Board |
| Stefanie Lang | Member of Supervisory Board |
| Regina Karsch | Member of Supervisory Board |
| Ralf Erkens | Member of Supervisory Board |
| Pascale Witz | Member of Supervisory Board |
| Frank Prescher | Member of Supervisory Board |
| Beate Haßdenteufel | Member of Supervisory Board |
| Dr. Marcus Kuhnert | Member of Supervisory Board |
| Dr. A. Sorensen | Member of Supervisory Board |
| Dr. Manuela Stauss-Grabo | Member of Supervisory Board |
| Activity Description |
|---|
|
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany. |
© 2000 - 2025 UniCredit Bank Austria AG. Please read our terms and conditions
Implemented and powered by FactSet
Fond data is provided from Mountain-View Data Gmbh
Austria-HomePage Version 2.0.54
